Wockhardt’s new antibiotic WCK 6777 gains FDA fast track status, completes phase I trial, stocks decline 1 min read Markets Wockhardt’s new antibiotic WCK 6777 gains FDA fast track status, completes phase I trial, stocks decline Daily News Express October 8, 2024 Wockhardt Limited announced today that its novel antibiotic WCK 6777 (Ertapenem/Zidebactam) has been granted Fast Track designation...Read More
